Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.59 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.50 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.50 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.50 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.50 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.50 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.50 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.50 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.50 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19625551 | 0.86 | MAPT (0.68) | KEAP1MAPTRXFP1SMN1; SMN2ALOX5 | |
| SCHEMBL6014474 | 0.85 | HDAC1 (0.64) | MAOAKEAP1MAPTRXFP1SMN1; SMN2 | |
| SCHEMBL19561359 | 0.84 | HDAC1 (0.69) | KEAP1MAPTRXFP1SMN1; SMN2ALOX5 | |
| SCHEMBL497371 | 0.84 | KEAP1 (0.73) | KEAP1MAPTRXFP1SMN1; SMN2ALOX5 | |
| SCHEMBL4886613 | 0.82 | MAPT (0.73) | KEAP1MAPTRXFP1SMN1; SMN2ALOX5 | |
| SCHEMBL712597 | 0.82 | KEAP1 (0.70) | KEAP1MAPTRXFP1SMN1; SMN2ALOX5 | |
| SCHEMBL107423 | 0.82 | KEAP1 (0.70) | KEAP1MAPTRXFP1SMN1; SMN2ALOX5 | |
| SCHEMBL12040749 | 0.81 | HPGD (0.61) | KEAP1MAPTRXFP1ALOX5HDAC3 | |
| SCHEMBL2170038 | 0.81 | KEAP1 (0.53) | KEAP1MAPTRXFP1SMN1; SMN2ALOX5 | |
| SCHEMBL11889075 | 0.81 | MAPT (0.56) | KEAP1MAPTRXFP1SMN1; SMN2ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11820728-B2 | Carbonyl lipids and lipid nanoparticle formulations for delivery of nucleic acids | Acuitas Therapeutics, Inc. (CA) | 2023-11-21 | — | — | US | disclosed |
| US-11820728-B2 | Carbonyl lipids and lipid nanoparticle formulations for delivery of nucleic acids | Acuitas Therapeutics, Inc. (CA) | 2023-11-21 | — | — | US | disclosed |
| US-20220081392-A1 | NOVEL CARBONYL LIPIDS AND LIPID NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACIDS | Acuitas Therapeutics, Inc. (CA) | 2022-03-17 | — | — | US | disclosed |
| US-9963454-B2 | Compounds and compositions for the treatment of parasitic disease | NOVARTIS AG (CH) | 2018-05-08 | — | — | US | disclosed |
| US-9469645-B2 | Compounds and compositions for the treatment of parasitic diseases | NOVARTIS AG (CH) | 2016-10-18 | — | — | US | disclosed |
| US-20160108051-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASE | NOVARTIS AG (CH) | 2016-04-21 | — | — | US | disclosed |
| US-20130281403-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | IRM LLC (BM) | 2013-10-24 | — | — | US | disclosed |
| US-8557801-B2 | Compounds and compositions useful for the treatment of parasitic diseases | IRM LLC (BM) | 2013-10-15 | — | — | US | disclosed |
| US-20110059934-A1 | COMPOUNDS AND COMPOSITIONS USEFUL FOR THE TREATMENT OF PARASITIC DISEASES | IRM LLC (BM) | 2011-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110059934-A1 | COMPOUNDS AND COMPOSITIONS USEFUL FOR THE TREATMENT OF PARASITIC DISEASES | SQLE, SGMS2, FDPS | MAOA 1419/4885KEAP1 254/4885MAPT 1239/4885 |
| US-11820728-B2 | Carbonyl lipids and lipid nanoparticle formulations for delivery of nucleic acids | TTPA, ACAA2, CPT2 | MAOA 2276/4885KEAP1 44/4885MAPT 8/4885 |
| US-20220081392-A1 | NOVEL CARBONYL LIPIDS AND LIPID NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACIDS | TTPA, ACAA2, POLRMT | MAOA 2494/4885KEAP1 73/4885MAPT 11/4885 |
| US-20160108051-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASE | SQLE, SGMS2, SGMS1 | MAOA 2068/4885KEAP1 220/4885MAPT 868/4885 |
| US-20130281403-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | SQLE, ABCB1, FDPS | MAOA 2066/4885KEAP1 114/4885MAPT 1020/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.